{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:05:09Z","timestamp":1769641509034,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the 2024 Science-Health Collaborative Research Program of the Wanzhou District, Chongqing","award":["wzwjw-kw2024034"],"award-info":[{"award-number":["wzwjw-kw2024034"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-02063-2","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:37:57Z","timestamp":1764765477000},"page":"284-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database"],"prefix":"10.1007","volume":"48","author":[{"given":"Yaping","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"1","key":"2063_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","volume":"10","author":"SI Hung","year":"2024","unstructured":"Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions. Nat Rev Dis Primers. 2024;10(1):30. https:\/\/doi.org\/10.1038\/s41572-024-00514-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2063_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.16316","volume":"80","author":"R Cadot","year":"2025","unstructured":"Cadot R, Gery P, Lenief V, et al. Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology. Allergy. 2025;80(1):47\u201362. https:\/\/doi.org\/10.1111\/all.16316.","journal-title":"Allergy"},{"issue":"6","key":"2063_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","volume":"25","author":"H Shah","year":"2024","unstructured":"Shah H, Parisi R, Mukherjee E, et al. Update on Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: diagnosis and management. Am J Clin Dermatol. 2024;25(6):891\u2013908. https:\/\/doi.org\/10.1007\/s40257-024-00889-6.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"2063_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70061","volume":"33","author":"B Javdan","year":"2024","unstructured":"Javdan B, Marwaha S, Wassef C, et al. Severe cutaneous adverse reactions in hospitalized children: a pilot validation study. Pharmacoepidemiol Drug Saf. 2024;33(12):e70061. https:\/\/doi.org\/10.1002\/pds.70061.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"2063_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1111\/bcp.16153","volume":"90","author":"SF Ramos","year":"2024","unstructured":"Ramos SF, do Sacramento LG, de Silva ROS, et al. Moderate and serious adverse reactions to antimicrobials among hospitalized children: a systematic review. Br J Clin Pharmacol. 2024;90(9):2092\u2013110. https:\/\/doi.org\/10.1111\/bcp.16153.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2063_CR6","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1111\/bcp.14958","volume":"88","author":"A Smits","year":"2022","unstructured":"Smits A, Annaert P, Cavallaro G, et al. Current knowledge, challenges and innovations in developmental pharmacology: a combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. Br J Clin Pharmacol. 2022;88(12):4965\u201384. https:\/\/doi.org\/10.1111\/bcp.14958.","journal-title":"Br J Clin Pharmacol"},{"key":"2063_CR7","doi-asserted-by":"publisher","first-page":"204209862312007","DOI":"10.1177\/20420986231200746","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Wu Y, Jiang T, et al. Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature. Ther Adv Drug Saf. 2023;14:20420986231200744. https:\/\/doi.org\/10.1177\/20420986231200746.","journal-title":"Ther Adv Drug Saf"},{"key":"2063_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2438744","author":"H Shan","year":"2025","unstructured":"Shan H, Wei C, Zhang J, et al. Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database. Expert Opin Drug Saf. 2025. https:\/\/doi.org\/10.1080\/14740338.2024.2438744.","journal-title":"Expert Opin Drug Saf"},{"key":"2063_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2278685","author":"L Zhou","year":"2023","unstructured":"Zhou L, Yang J, Xiao M, et al. Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events. Expert Opin Drug Saf. 2023. https:\/\/doi.org\/10.1080\/14740338.2023.2278685.","journal-title":"Expert Opin Drug Saf"},{"key":"2063_CR10","doi-asserted-by":"publisher","first-page":"1117391","DOI":"10.3389\/fphar.2023.1117391","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Gou J, Zhu J, et al. Severe cutaneous adverse reactions to drugs: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Front Pharmacol. 2023;14:1117391. https:\/\/doi.org\/10.3389\/fphar.2023.1117391.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2063_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43441-022-00393-1","volume":"57","author":"I Gro\u00dfe-Michaelis","year":"2023","unstructured":"Gro\u00dfe-Michaelis I, Proestel S, Rao RM, et al. MedDRA labeling groupings to improve safety communication in product labels. Ther Innov Regul Sci. 2023;57(1):1\u20136. https:\/\/doi.org\/10.1007\/s43441-022-00393-1.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"2063_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12911-024-02801-y","volume":"24","author":"BH Rekha","year":"2024","unstructured":"Rekha BH, Hisham SA, Wahab IA, et al. Digital monitoring of medication safety in children: an investigation of ADR signalling techniques in Malaysia. BMC Med Inform Decis Mak. 2024;24(1):395. https:\/\/doi.org\/10.1186\/s12911-024-02801-y.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"4","key":"2063_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/archdischild-2019-318676","volume":"106","author":"FB Lagler","year":"2021","unstructured":"Lagler FB, Hirschfeld S, Kindblom JM. Challenges in clinical trials for children and young people. Arch Dis Child. 2021;106(4):321\u20135. https:\/\/doi.org\/10.1136\/archdischild-2019-318676.","journal-title":"Arch Dis Child"},{"issue":"4","key":"2063_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13793","volume":"17","author":"PD Maglalang","year":"2024","unstructured":"Maglalang PD, Wen J, Hornik CP, et al. Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population. Clin Transl Sci. 2024;17(4):e13793. https:\/\/doi.org\/10.1111\/cts.13793.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2063_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40360-019-0285-y","volume":"20","author":"Y Du","year":"2019","unstructured":"Du Y, Lin J, Shen J, et al. Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015. BMC Pharmacol Toxicol. 2019;20(1):7. https:\/\/doi.org\/10.1186\/s40360-019-0285-y.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2063_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.phrs.2016.11.027","volume":"115","author":"E Ram\u00edrez","year":"2017","unstructured":"Ram\u00edrez E, Bell\u00f3n T, Tong HY, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS\/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168\u201378. https:\/\/doi.org\/10.1016\/j.phrs.2016.11.027.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2063_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s42494-025-00223-5","volume":"7","author":"J Gui","year":"2025","unstructured":"Gui J, Wang L, Meng L, et al. Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database. Acta Epileptol. 2025;7(1):31. https:\/\/doi.org\/10.1186\/s42494-025-00223-5.","journal-title":"Acta Epileptol"},{"key":"2063_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2468351","author":"Z Wu","year":"2025","unstructured":"Wu Z, Zhao Y, Zhang X, et al. Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis. Expert Opin Drug Saf. 2025. https:\/\/doi.org\/10.1080\/14740338.2025.2468351.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2063_CR19","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1093\/ajhp\/zxae294","volume":"82","author":"HM Chua","year":"2025","unstructured":"Chua HM, Limenta M, Ng CYL, et al. Implementation of HLA-related genotype-guided prescribing in Singapore. Am J Health Syst Pharm. 2025;82(5):e285\u201393. https:\/\/doi.org\/10.1093\/ajhp\/zxae294.","journal-title":"Am J Health Syst Pharm"},{"key":"2063_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3389\/fphar.2020.00969","volume":"11","author":"CJ Chang","year":"2020","unstructured":"Chang CJ, Chen CB, Hung SI, et al. Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions. Front Pharmacol. 2020;11:969. https:\/\/doi.org\/10.3389\/fphar.2020.00969.","journal-title":"Front Pharmacol"},{"key":"2063_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177679","volume":"999","author":"X Xia","year":"2025","unstructured":"Xia X, Wang J, Jia X, et al. Comparison of safety signals for ibuprofen in children and adults: a real-world pharmacovigilance analysis. Eur J Pharmacol. 2025;999:177679. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177679.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2063_CR22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00431-025-06068-x","volume":"184","author":"AP Metbulut","year":"2025","unstructured":"Metbulut AP, Haci \u0130A, Can D, et al. Evaluation of drug-related anaphylaxis in children: multi-center study. Eur J Pediatr. 2025;184(3):230. https:\/\/doi.org\/10.1007\/s00431-025-06068-x.","journal-title":"Eur J Pediatr"},{"key":"2063_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.896867","volume":"10","author":"QH Shao","year":"2022","unstructured":"Shao QH, Yin XD, Zeng N, et al. Stevens-Johnson syndrome following non-steroidal anti-inflammatory drugs: a real-world analysis of post-marketing surveillance data. Front Pediatr. 2022;10:896867. https:\/\/doi.org\/10.3389\/fped.2022.896867.","journal-title":"Front Pediatr"},{"issue":"7","key":"2063_CR24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65284","volume":"16","author":"P Dhage","year":"2024","unstructured":"Dhage P, Mali S, Pawar S, et al. Prospective analysis of cutaneous adverse drug reactions encountered in a tertiary care hospital. Cureus. 2024;16(7):e65284. https:\/\/doi.org\/10.7759\/cureus.65284.","journal-title":"Cureus"},{"issue":"3","key":"2063_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/derm.2023.0258","volume":"35","author":"AK \u00d6zhan","year":"2024","unstructured":"\u00d6zhan AK, Demirhan A, Arikoglu T, et al. Toxic skin reactions should be differentiated from allergic reactions to chemotherapeutic drugs in children: a case series and review of the literature. Dermatitis. 2024;35(3):275\u201387. https:\/\/doi.org\/10.1089\/derm.2023.0258.","journal-title":"Dermatitis"},{"issue":"10","key":"2063_CR26","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/ijd.17850","volume":"64","author":"IA Koumprentziotis","year":"2025","unstructured":"Koumprentziotis IA, Niforou A, Tsimpidakis A, et al. Dupilumab for the treatment of cutaneous immune-related adverse events: a systematic review. Int J Dermatol. 2025;64(10):1825\u201332. https:\/\/doi.org\/10.1111\/ijd.17850.","journal-title":"Int J Dermatol"},{"issue":"2","key":"2063_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcp.13445","volume":"84","author":"B Lebrun-Vignes","year":"2018","unstructured":"Lebrun-Vignes B, Guy C, Jean-Pastor MJ, et al. Is acetaminophen associated with a risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. Br J Clin Pharmacol. 2018;84(2):331\u20138. https:\/\/doi.org\/10.1111\/bcp.13445.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2063_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11096-013-9777-9","volume":"35","author":"S Tiamkao","year":"2013","unstructured":"Tiamkao S, Jitpimolmard J, Sawanyawisuth K, et al. Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm. 2013;35(4):608\u201312. https:\/\/doi.org\/10.1007\/s11096-013-9777-9.","journal-title":"Int J Clin Pharm"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02063-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:19:01Z","timestamp":1768972741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02063-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2063"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02063-2","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Because FAERS is a publicly available and de-identified database, this study did not require institutional ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}